Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

ABSTRACT:

Background

High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the use of combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in this population have raised questions about the role and timing of transplantation.

Methods

We randomly assigned 700 patients with multiple myeloma to receive induction therapy with three cycles of RVD and then consolidation therapy with either five additional cycles of RVD (350 patients) or high-dose melphalan plus stem-cell transplantation followed by two additional cycles of RVD (350 patients). Patients in both groups received maintenance therapy with lenalidomide for 1 year. The pri

SUBMITTER: Attal M 

PROVIDER: S-EPMC6201242 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature